Point72 Hong Kong LTD Abb Vie Inc. Call Options Transaction History

Point72 Hong Kong LTD

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $2.52 Million - $2.89 Million	-18,800 Reduced 59.49%	12,800 $1.72 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $949,578 - $1.21 Million	6,900 Added 27.94%	31,600 $4.84 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $3.01 Million - $3.73 Million	22,800 Added 1200.0%	24,700 $4 Million
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $1.26 Million - $1.59 Million	-11,700 Reduced 86.03%	1,900 $257,000
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $180,880 - $205,326	1,700 Added 14.29%	13,600 $1.47 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $2.47 Million - $2.75 Million	-23,500 Reduced 66.38%	11,900 $1.34 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $143,220 - $157,668	1,400 Added 4.12%	35,400 $3.83 Million
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $2.74 Million - $3.69 Million	34,000 New	34,000 $3.64 Million

3,808

1.27B

13M

9.94M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.